A meta-analysis of multiple matched aCGH/expression cancer datasets reveals regulatory relationships and pathway enrichment of potential oncogenes

Richard Newton☯*, Lorenz Wernisch☯

MRC Biostatistics Unit, Cambridge University, Cambridge, United Kingdom

☯ These authors contributed equally to this work.
* richardhnewton@gmail.com

Abstract

The copy numbers of genes in cancer samples are often highly disrupted and form a natural amplification/deletion experiment encompassing multiple genes. Matched array comparative genomics and transcriptomics datasets from such samples can be used to predict inter-chromosomal gene regulatory relationships. Previously we published the database META-MATCHED, comprising the results from such an analysis of a large number of publically available cancer datasets. Here we investigate genes in the database which are unusual in that their copy number exhibits consistent heterogeneous disruption in a high proportion of the cancer datasets. We assess the potential relevance of these genes to the pathology of the cancer samples, in light of their predicted regulatory relationships and enriched biological pathways. A network-based method was used to identify enriched pathways from the genes’ inferred targets. The analysis predicts both known and new regulator-target interactions and pathway memberships. We examine examples in detail, in particular the gene POGZ, which is disrupted in many of the cancer datasets and has an unusually large number of predicted targets, from which the network analysis predicts membership of cancer related pathways. The results suggest close involvement in known cancer pathways of genes exhibiting consistent heterogeneous copy number disruption. Further experimental work would clarify their relevance to tumor biology. The results of the analysis presented in the database METAMATCHED, and included here as an R archive file, constitute a large number of predicted regulatory relationships and pathway memberships which we anticipate will be useful in informing such experiments.

Introduction

Previously we have demonstrated that an analysis of matched array comparative genomics and transcriptomics human cancer datasets can reveal inter-chromosomal acting gene regulatory relationships [1–3]. By regulatory relationship we are referring to either a direct relationship, of
a transcription factor on its target gene, or a very indirect one, through a pathway containing intermediate regulatory steps. We published the database METAMATCHED [4], comprising the results from such an analysis of a large number of publically available cancer datasets. Careful data randomisation ensures statistically significant predictions. Each dataset originated from samples of a particular type of cancer, and the datasets covered a wide range of cancer types.

We noticed that there are genes in the database which have a highly variable copy number amongst samples within a dataset and this occurs consistently for these same genes across many of the datasets and different cancer types. In this paper we investigate these unusual genes. We investigate their target genes, predicted by the meta-analysis of publically available cancer datasets, the biological pathways enriched in their lists of target genes, and their relevance to the cancer pathology of the samples. Why genes which have a highly variable, inconsistent copy number disruption amongst samples within a cancer dataset may, perhaps counter-intuitively, be of relevance to the cancer pathology is examined later in this introduction. Firstly we discuss the background to the meta-analysis and the pathway enrichment analysis.

Array comparative genomics (aCGH) microarrays detect gene deletions or gene amplifications (extra copies) by comparing gene copy numbers in the DNA extracted from test sample cells to the copy numbers in normal control cells. Transcriptomics experiments use microarrays that measure the abundance of mRNA. In matched experiments the two different types of measurement are performed on the same samples. Reviews of matched aCGH and transcriptomics experiments, their analysis and uses can be found in references [5] and [6].

In cancer samples the copy numbers of genes are often greatly altered and are in effect of a natural gene amplification/deletion experiment encompassing many genes. In matched experiments, transcriptomics data is also available for the same samples, and information can be extracted on how changes in a gene’s copy number affects that gene’s expression. The analysis can however be extended further, using the measurements to investigate whether a change in a given gene’s copy number, with an associated change in expression, affects the expression of any of the other genes in the dataset, hence inferring regulatory relationships.

Inference of regulatory relationships from these experiments is not without difficulties. Relationships are masked by the noise in the data and further confounded by the biological complexity of the system being studied. In particular, unlike conventional gene knockdown experiments, the copy number of many genes are being perturbed simultaneously. Coamplification or codeletion of genes situated in the same region of the genome can produce many spurious relationships and it is for this reason that we concentrate on inter-chromosomal acting regulatory relationships.

We validated the hypothesis that useful regulatory information can be extracted from matched datasets, experimentally in Goh et al. [1] and computationally in Newton and Werhner [2]. We then performed a meta-analysis of 31 publically available datasets [3]. These comprised matched experiments from a variety of different cancer types. Genes that have altered copy number in one cancer type may have altered copy number in other cancer types [7], so combining datasets should help reinforce any information within the data on regulator-target relationships. The results were made available in the METAMATCHED database [4]. For this paper we have extended the meta-analysis to 45 datasets. The 14 extra datasets contain 824 samples, taking the total number of samples in the meta-analysis to 3398 samples.

The meta-analysis predicts target lists for regulatory genes. In this paper, to augment this information, we investigate the enrichment of biological pathways in the target lists. To this end, we used a network-based pathway enrichment approach. An enrichment analysis based on the network of a pathway, rather than simply the gene set of the pathway, takes into
consideration the interactions between the genes in the pathway. We use PathwayCommons network databases [8] and the local enrichment analysis (LEAN) method of Gwinner et al. [9] for network analysis of target lists, and then assess the resulting output for biological pathway enrichment using a hypergeometric test. The results of the analysis are presented in the Meta-matched database and are also included in this paper’s supplementary material as an R [10] archive file (S3 File).

The aim of the pathway enrichment analysis is three-fold. Firstly, statistically significance enrichments can help to validate the predictions of regulatory relationships generated by the meta-analysis of the matched datasets. Secondly, the enrichment of a regulatory gene’s predicted target gene list in a particular pathway can be used to augment current knowledge of that pathway. Thirdly, the enrichment analysis can be used to investigate the participation of the regulators in pathways implicated in cancers, which is the main focus of this paper.

We are using cancer samples to predict regulatory relationships because they can be seen as a natural gene amplification/deletion experiment. That the disruptions are outside our control does mean however that inference about regulatory relationships will only be possible for certain genes. Those genes with high variation in their copy number amongst the samples within a dataset will show the highest self aCGH/expression correlation, provided of course that there is a concomitant change in expression. Conversely, if a gene is not amplified or deleted in any sample in a dataset, or if it is amplified or deleted by a similar amount in all the samples, then little or no self aCGH/expression correlation will be detected and the analysis will be unable to reveal any regulatory relationships for the gene. This means that any oncogenes which are consistently amplified or deleted in cancer samples are unlikely to feature in the results.

We find that there are a number of genes which have a highly variable copy number amongst samples within a dataset and this occurs consistently across many of the datasets and a very wide variety of different cancer types. There are 47 genes which have significant self aCGH/expression correlation (and predicted targets) in twenty or more datasets. In this paper we assess the potential relevance to the pathology of the cancer samples of genes exhibiting this unusual, consistent heterogeneous copy number disruption in light of their predicted regulatory relationships and enriched biological pathways. A prominent example of such a gene, that also has an unusually large number of target genes predicted by the meta-analysis, is POGZ (Pogo Transposable Element Derived With ZNF Domain) and we examine in detail some of the novel pathway involvements predicted for this interesting gene.

It may appear counter-intuitive that genes whose copy number disruption varies greatly between the different cancer samples within a dataset could be relevant to tumor biology. It would suggest that these genes are located in genomic regions which are prone to disruption in cancer cells, but this disruption occurs only sporadically amongst samples. And this inconsistency would suggest that the disruption of these regulators would have little relevance to the actual cancer pathology. It is known however that few genes are altered in more than 10% of tumors for any type of cancer [11] and there is a complex interplay of alterations within pathways in cancers [12]. So it is possible that disruption of several different gene members of a particular pathway, in an inconsistent manner across the various cancer samples in a dataset could result in that pathway being consistently disrupted in all the samples of that cancer type.

Alternatively, these genes may occur in genomic regions which are disrupted, not sporadically, but consistently in the later stages of tumor development. In general the samples within a dataset will come from tumors at different stages of the disease, so the disruption to these particular genes may reflect changes that take place during the course of tumor development. These points are examined further in the Discussion section.

The aim of the work described in this paper was two-fold. Firstly, to augment the information held in the Metamatched database with a comprehensive pathway enrichment analysis.
This has added predictions of pathway memberships, as well as predictions of regulatory relationships to the database, and we give examples of the usefulness of these predictions in the following. Secondly, the aim was to explore the relevance of the information in the database to cancer, concentrating on particular prominent regulators highlighted by the meta-analysis. We present arguments as to why these genes could play a role in tumor biology, which appears to be supported by the pathway enrichment results.

**Materials and methods**

In this section we first give a brief summary of the previously published meta-analysis method we use to predict gene regulatory relationships. We then describe the network-based pathway enrichment approach we use in this paper to analyse the results from the meta-analysis. Fig 1 is a flow chart illustrating all the steps involved in the analysis from array data through to enriched pathways.

**Prediction of regulatory relationships**

We infer inter-chromosomal acting gene regulatory relationships from a meta-analysis of 45 matched aCGH/transcriptomics datasets, which are listed in Table 1. We use a method based on correlations, a robust approach for analysing relationships amongst large amounts of data of unknown complexities. More sophisticated network inference methods are generally more likely to be susceptible to noise and heterogeneity between datasets. A major advantage of our method is that it avoids the risk of confounding that can occur when expression data alone is used in the analysis. Careful data randomisation to generate a null distribution is used to ensure statistically significant predictions. Full details of the algorithm can be found in references [3], [2] and in [1], where the code, written in the R statistical environment [10], can also be found. The details are also provided in supplementary information S1 File.

We refer to a ‘regulating gene’ or ‘regulator’ as one whose up or down expression change has a direct or indirect effect on the up or down regulation of a ‘target gene’. Any gene whose mRNA expression levels are significantly correlated with changes in its own copy number is considered worth investigating as a potential regulating gene. A potential target gene of a regulating gene has expression levels which are significantly correlated with the copy number alterations of the regulating gene.

A gene appearing in a regulator’s list of predicted targets, does not mean that regulator is the most probable regulator for that target. Therefore, for each potential regulator, all predicted targets were assessed to see if the data indicated a more probable gene as its regulator. There are two possible criteria for assigning the best regulator for a target gene: either by minimum \( p \)-value from the meta-analysis or by the maximum number of datasets where there is significant correlation between the target’s expression and the regulator’s aCGH.

In the following we use the short-hand ‘significant best target’ to refer to a predicted target of a regulator which is first of all significant \((p\text{-value}<0.05)\). Moreover this regulator is predicted to be the best regulator for the target out of all the regulators in the MetaMatched analysis by way of both minimum \( p \)-value and having the maximum number of datasets where there is significant correlation between the target’s expression and the regulator’s aCGH. We use the short-hand ‘less stringent condition for best regulator’ to refer to assigning a regulator as the best regulator of a target by way of either minimum \( p \)-value or having the maximum number of datasets where there is significant correlation between the target’s expression and the regulator’s aCGH.
Fig 1. Schematic diagram showing the steps involved in the analysis.

https://doi.org/10.1371/journal.pone.0213221.g001

A meta-analysis reveals regulatory relationships and pathway enrichment of potential oncogenes
Table 1. Details of the 45 datasets used in the meta-analysis, the original 31 followed by the 14 new datasets.

| Code | GEO     | Publication | N   | P     | Pathology                        |
|------|---------|-------------|-----|-------|----------------------------------|
| parr | GSE20486| [13]        | 97  | 18616 | Breast Cancer (Diploid)          |
| crow | GSE15134| [14]        | 31  | 16153 | Breast Cancer (ER+)              |
| sirc | GSE17907| [15]        | 51  | 14689 | Breast Cancer (ERBB2 amplified)  |
| myll | †       |             | 46  | 17050 | Gastric Cancer                   |
| junn | †       |             | 10  | 16844 | Gastric Cancer                   |
| ch.w | †       |             | 91  | 10285 | Lung adenocarcinoma              |
| ch.s | †       |             | 94  | 10285 | Lung adenocarcinoma              |
| hoac | GSE20154| [19]        | 54  | 14388 | Oesophageal adenocarcinoma        |
| zho  | GSE29023| [20]        | 115 | 13697 | Multiple Myeloma                 |
| shai | GSE26089| [21]        | 68  | 14201 | Pancreatic Cancer                |
| vain | GSE28403| [22]        | 13  | 10107 | Prostate Cancer                  |
| bott | GSE29211| [23]        | 53  | 10321 | Pleural Mesothelioma             |
| bekh | GSE23720| [24]        | 173 | 13682 | Breast Cancer (Inflammatory)     |
| chap | GSE28663| [25]        | 245 | 13667 | Multiple Myeloma                 |
| ooi  | GSE22785| [26]        | 14  | 10091 | Neuroblastoma                    |
| brag | GSE12668| [27]        | 11  | 10310 | Waldenstrom’s Macroglobulinemia  |
| jons | GSE22133| [28]        | 356 | 4183  | Breast Cancer                    |
| mura | GSE24707| [29]        | 47  | 4472  | Breast Cancer                    |
| lin1 | GSE19915| [30]        | 72  | 4965  | Urothelial Carcinoma             |
| beck | GSE17555| [31]        | 18  | 12174 | Leiomyosarcoma                   |
| toed | GSE18166| [32]        | 74  | 4289  | Astrocytic Gliomas               |
| ell  | GSE35191| [33]        | 124 | 13569 | Breast Cancer                    |
| gra.1| GSE35988| [34]        | 85  | 12849 | Prostate Cancer                  |
| gra.2| GSE35988| [34]        | 34  | 12813 | Prostate Cancer                  |
| lenz | GSE11318| [35]        | 203 | 15212 | Lymphoma                         |
| lin2 | GSE32549| [36]        | 131 | 8450  | Urothelial Carcinoma             |
| micc | GSE38230| [37]        | 12  | 16657 | Vulva Squamous Cell Carcinoma    |
| tayl | GSE21032| [38]        | 155 | 14572 | Prostate Cancer                  |
| coco | GSE25711| ‡           | 36  | 4394  | Neuroblastoma                    |
| med  | GSE14079| [40]        | 8   | 6376  | Lung Cancer                      |
| przy | GSE54188| [41]        | 53  | 17032 | Synovial Sarcoma                 |
| huang| GSE30311| [42]        | 98  | 14927 | Ovarian Cancer                   |
| lira | GSE34211| [43]        | 89  | 14907 | Cancer Cell lines                |
| chpy.1| GSE34171| [44]        | 87  | 14907 | Diffuse Large B-cell Lymphoma    |
| chpy.2| GSE34171| [44]        | 78  | 10437 | Diffuse Large B-cell Lymphoma    |
| ross | GSE70770| [45]        | 78  | 15150 | Prostate Cancer                  |
| ochs | GSE33232|            | 69  | 14489 | Head and Neck Squamous Cell Carcinoma |
| rama | GSE19539| [46]        | 67  | 14972 | Ovarian Cancer                   |
| guar | GSE6399 | [47]        | 65  | 14833 | Breast Cancer                    |
| wilk | GSE36471| [48]        | 47  | 13681 | Lung Adenocarcinoma              |
| dona | GSE26688| [49]        | 32  | 14833 | Pancreatic Cancer                |
| zha  | GSE12805|            | 31  | 11639 | Osteosarcoma                     |
| kuij | GSE33383| [50]        | 29  | 14339 | Osteosarcoma                     |
| pasi | GSE26576| [51]        | 29  | 14883 | Diffuse Intrinsic Pontine Glioma |
| weig | GSE57549| [52]        | 25  | 15150 | Breast Cancer                    |

GEO = Gene Expression Omnibus dataset reference (http://www.ncbi.nlm.nih.gov/geo/), N = Number of samples, P = Number of matched probes,

* http://www.cangem.org/,
† http://chic.mskcc.org/Public/lung_array_data/,
‡ Expression data in ArrayExpress (http://www.ebi.ac.uk/arrayexpress/): E-TABM-38, E-MTAB-161. Expts. ch, gra & chpy. use 2 expr. platforms, so samples from each platform treated as separate dataset, to avoid spurious correlations which may be caused by systematic shifts between the 2 sets of expr. data. Each contributes 2 datasets to study, resulting in 45 d’sets from 42 expts.

https://doi.org/10.1371/journal.pone.0213221.t001
Network-based pathway enrichment analysis

**Introduction.** For each regulator, pathway enrichment was investigated separately using a network based analysis of the list of its target genes. The networks used were four databases of gene interactions in PathwayCommons [8], namely Humancyc (v20; 2016) [53], Panther (v3.6.1; 25-Jan-2018) [54], Pid (NCI Curated Human Pathways; 27-Jul-2015) [55] and Reactome (v64; 26-Mar-2018) [56], in the SIF (Simple interaction file) format. In the four databases there are a total of 9849 pathways, whose membership ranged from 2 to 2405 genes.

The SIF format is a flat-file compendium of pairwise gene interactions documenting on each line two genes, the nature of their interaction (comprising one of eight different interaction types), and a biological pathway annotation for the interaction and/or a Pubmed ID (PMID) [57]. Not all interactions are annotated with a pathway or PMID and the pathway annotations may be composite pathways, each member in the list being separated by a semicolon. We use the term node of the network to refer to a gene and the term edge of the network to refer to the undirected interaction between two genes. In the following pathway analysis we will make use of this annotation of edges by pathways. We refer to a gene as being annotated with a pathway if at least one of the edges connected to the gene is annotated with the pathway.

The analysis consisted of two steps. Firstly the target gene list of the regulator was analysed in order to find enrichment of local subnetworks within the given PathwayCommons network database. Then the set of enriched local subnetworks discovered in the first step were investigated for the presence of enriched biological pathways according to the pathway annotations in the PathwayCommons database. Fig 2 shows a flow diagram of the different steps in the analysis, which are described in the following two sections.

**Network analysis.** The local enrichment analysis (LEAN) method of Gwinner et al. [9] was used for the network analysis. The purpose of this analysis is to find subnetworks of genes which together have unusually low p-values. The LEAN method examines local subnetworks, each of which comprises a single centre gene and its direct neighbours in a network database. All possible local subnetworks (centre genes) are evaluated. Evaluation of a local subnetwork takes as input the p-values of the centre gene and its direct neighbours, calculates an enrichment score and uses a null distribution derived from random sampling to return an enrichment p-value. The parameter free and exhaustive aspect of the LEAN method makes it particularly suitable for a comprehensive analysis of large numbers of disparate gene lists.

For a regulator, the input to the LEAN algorithm was the complete list of target gene p-values from the meta-analysis for this regulator. That is, the p-values for the correlation between the regulator’s aCGH and the target genes’ expression. For each target gene the minimum of the p-value for activation by the regulator and the p-value for repression by the regulator was selected.

A gene was considered to be an enriched centre gene, at the centre of a significantly enriched subnetwork, if the LEAN p-value for the local subnetwork was less than 0.05.

**Pathway enrichment analysis.** The LEAN analysis of a regulator’s target gene list generates a number of significantly enriched local subnetworks for a given PathwayCommons network database. In this step the results of the network analysis are summarised and condensed in order to extract significantly enriched biological pathways.

The following procedure was carried out for each regulator in each PathwayCommons network database in which the regulator shows significant enrichment of its target list. For each significantly enriched local subnetwork found for the regulator, biological pathways associated with the subnetwork were recorded by noting the pathways assigned to the edges of the subnetwork in the PathwayCommons network database. Not all edges were included; only the
Fig 2. Schematic diagram showing the steps involved in the network-based pathway enrichment analysis.

https://doi.org/10.1371/journal.pone.0213221.g002
edges attached to a gene for which the regulator is predicted to be the best regulator and where this regulator-target relationship is significant ($p$-value < 0.05). The stringent rule was applied as to whether a regulator is predicted to be the best regulator for a target gene.

The results of applying this procedure for all the significantly enriched local subnetworks of the regulator were collated to give a list of pathways and the number of enriched centre genes associated with each of the pathways. The hypergeometric distribution was then used to test whether the number of occurrences for a particular pathway was more than expected by chance.

The hypergeometric distribution provides the distribution of finding $k$ objects with a certain feature in a random sample of size $n$ out of a population of $N$ objects where a total of $K$ objects has this feature. Here $k$ is the number of enriched centre genes associated with a pathway, $n$ is the total number of enriched centre genes in the LEAN analysis for this regulator, $K$ is the number of genes recorded as being members of this pathway in the PathwayCommons database and $N$ is the total number of genes in the PathwayCommons database. Significantly enriched pathways were selected as those with adjusted $p$-value from the hypergeometric test less than 0.05.

The pathway with the minimum hypergeometric $p$-value was recorded as the main pathway for the regulator. As well as using the pathways in the PathwayCommons databases, the analysis used the Pubmed Ids if an interaction was not annotated with an actual pathway name.

If a regulator itself was not annotated on any of its edges with one of its significantly enriched pathways then the R package igraph [58] was used to discover whether the regulator had any path in the network database to any of the genes whose edges were annotated with the pathway. The package igraph was also used to create plots of the significantly enriched pathways for a regulator. The biological pathways derived from the combined local subnetworks could be too large for plotting and required some pruning. S1 File contains details of how this was performed.

**Results**

In this section we first summarize the results of the meta-analysis. We then describe the primary results of the paper, namely the outcome of the network-based pathway enrichment analysis. We first provide an overview of these results and then concentrate on genes exhibiting consistent heterogeneous copy number disruption, examining some of their enriched pathways in detail and their relevance to cancer biology.

**Meta-analysis**

From the meta-analysis of 45 matched aCGH/transcriptomics datasets we infer inter-chromosomal acting gene regulatory relationships. The complete results of the analysis can be found in the METAMATCHED database [4]. A description of the composition of the database can be found in S1 File. The analysis found 15496 genes considered worth investigating as potential regulators; that is, having significant correlation (adjusted $p$-value < 0.05) between their copy number profile and gene expression profile in at least one of the datasets. Of the 15496 potential regulators, 1176 were found to have at least one significant predicted target (adjusted $p$-value < 0.05). S2 File is a spreadsheet that summarises the results for the regulatory genes. The complete results, in R archive format are available for download from the Metamatched website, and are also included here as supplementary file S3 File.

**Network analysis**

The target gene list of each regulator was analysed for enrichment of local subnetworks within four PathwayCommons network databases using the LEAN method [9]. The set of enriched
local subnetworks were then investigated for the presence of enriched biological pathways using a hypergeometric test. After the results from the LEAN analysis have been summarised and condensed in this way a total of 250 regulators show significant pathway enrichment of their target gene lists. Each regulator that demonstrates some pathway enrichment is assigned a main pathway (or Pubmed ID) as described in the Methods section. The 250 regulators have a total of 152 unique main pathways (see Table A in S4 File). The number of genes assigned to the 152 main pathways in the PathwayCommons database ranged from 5 to 262 genes, with a mean of 65.

Each regulator will, in general, have a number of significantly enriched pathways besides a main pathway; the number ranges from 1 to 89 pathways, with a mean of 5. The 250 regulators between them have a total of 663 unique enriched pathways (see Table B in S4 File).

Summary pathway enrichment information is displayed for each of the regulators on its webpage in the Metamatched database. More detailed information can be downloaded from the web page; a spreadsheet summarises the pathway enrichment results, an R archive file contains comprehensive information on the enrichment of each of the pathways and plots on the web page illustrate these pathways.

We classified the enriched pathways into twenty major pathway types based on the top-level pathway classifications in Reactome. We assessed the frequency of occurrence of each pathway type by counting the number of regulators with target lists which are enriched with at least one pathway of the pathway type. In the sum of the number of regulators enriched with a particular pathway type the values were weighted by the number of datasets in which each regulator showed significant self aCGH/expression correlation. However, the number of genes annotated with a top-level pathway type in the PathwayCommons databases vary greatly, so the frequencies of occurrence of a pathway type were corrected for the number of annotated genes. Frequencies of occurrence were normalised so that the highest value was one.

A pathway type will feature high in the ranking if it is enriched in the target lists of many regulators and these regulators have self aCGH/expression correlation in many datasets, and hence many types of cancer. The results are shown in Fig 3. The most frequently occurring pathway types were Metabolism of RNA, Gene Expression (primarily RNA Polymerase II Transcription) and DNA Repair (primarily DNA Double-Strand Break Repair).

Genes exhibiting consistent heterogeneous copy number disruption

We focus on those regulatory genes which have significant correlation between their aCGH profiles and their own expression profiles in the highest number of datasets. The top genes in this respect are listed in Table 2, which gives the number of datasets in which significant self aCGH/expression correlation is found, the number of significant targets for which the gene is the best regulator from the meta-analysis and the main pathway for the gene from the network analysis.

The full list can be found in Table D in S4 File. This information is also displayed graphically in Fig 4 which plots for each regulator the number of significant best targets against the number of datasets in which it shows significant self aCGH/expression correlation. There are genes in the Metamatched analysis which show significant self correlation in a higher number of datasets (up to 28 datasets, see S2 File), but which do not have significantly enriched pathways so are not included in Fig 4.

In the following we examine some of the enriched pathways of these regulatory genes in detail in order to assess their potential relevance to tumor biology. Enrichment of a pathway in a gene’s target list can also provide further evidence for previously known interactions...
amongst genes or validate the predictions made by the Metamatched analysis. In addition it can be used to predict novel participants in pathways in two ways.

Firstly, if a regulator is not currently known to participate in a pathway, but the regulator’s target list is enriched in that pathway, the enrichment suggests that the regulator has a connection with the pathway and some effect on the pathway’s function. We investigated whether each regulator was already known to be part of its enriched pathways or had any network path to any known member of the pathways in the relevant PathwayCommons database. We found that 118 of the regulators are known to be connected to all their enriched pathways, 100 to none, and the remaining 32 to some of their enriched pathways. In Table B in S4 File, which tabulates each of the 663 enriched pathways, the regulators associated with a pathway are divided into those that are known to be connected to the pathway and those that are not known to be connected to the pathway.

Secondly, even if a regulator is already known to be part of a pathway for which its target gene list is enriched, in general there will be genes in its target gene list which are not known to be associated with the pathway. The prediction of these genes as targets of the regulator suggests they may be participants in the pathway. In general, the majority of a regulator’s significant best targets are not known to be involved in its enriched pathways (see Methods section for definition of ‘significant best target’). The details of the network analysis for each regulator that can be downloaded from the Metamatched website includes, for each enriched pathway, those significant best targets which are known to be connected to the pathway and those which are not known to be connected.

In the examples we concentrate on some of the pathways found to be the most disrupted pathways in the 45 datasets used in the analysis. As a measure of the disruption of a pathway we used the number of datasets in which at least one regulator associated by enrichment with this pathway has significant copy number disruption, with a concomitant change in expression. The top disrupted pathways are listed in Table 3 and the full list is given in Table C in S4 File. Note that the pathway entries for gene pairs in PathwayCommons may be composite pathways, separated by a semi-colon. In the LEAN analysis these composite pathways have
been used, but in compiling Table 3 composite entries have first been split into their component pathways. For brevity in the table, if two pathways are found to have exactly the same complement of regulators associated with them by enrichment then the pathways have been concatenated by a vertical-bar symbol. This generates 353 unique pathways, or pathway combinations, from the 663 composite pathways.
We now look at three examples of enriched pathways in detail (a further two are given in supplementary information S5 File):

**Pathway example 1: Formation of the beta-catenin:TCF transactivating complex.**

Beta-catenin plays an important part in the Wnt-signaling pathway and is itself controlled by binding partners such as the TCF family of transcription factors that affect its stability and localization. It participates in various processes such as gene expression and cell adhesion. Mutations in beta-catenin and the partners regulating its stability can contribute to tumorgenesis [61].

Thirteen regulators have this pathway as one of their enriched pathways, namely BCL9 (21), POGZ (20), RBBP5 (16), WWOX (16), CPEB4 (9), MYC (8), PYGO2 (7), LYL1 (3), ZNF446 (3), HOXD9 (2), NIPAL4 (2), RAB3A (2) and HIST2H2BE (2). The numbers in brackets indicate the number of datasets in which the regulator has significant self aCGH/expression correlation.

*BCL9 (B Cell CLL/Lymphoma 9)* has significant self-correlation in 21 datasets. It is known to be part of this pathway, being annotated with the pathway in Reactome.

*POGZ (Pogo Transposable Element Derived With ZNF Domain)*, a protein coding gene, has significant self-correlation in 20 of the datasets in Metamatched (Table 2). It also has an
## Table 3. Most disrupted pathways in the 45 datasets used in the analysis.

| Pathway                                                                 | Regulators                                                                 | N  |
|------------------------------------------------------------------------|----------------------------------------------------------------------------|----|
| Downstream TCR signaling                                               | ABCC12 ARHGEF4 ATXN7L2 HSBP1 IGSF9 MEF2C MN1 PBXIP1 PIK3R1 PIK51A PLCG2 POZG P5MB10 PTK2 RASGRF2 TERF2IP VHL | 33 |
| Generation of second messenger molecules                               | ARHGEF4 ATXN7L2 HSBP1 PIK51A PLCG2 POZG PTK2 TERF2IP VHL                  | 33 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ABCC12 ARHGEF4 ATXN7L2 ETV7 GALE IGSF9 INTS8 MCMDC2 MEF2C MN1 PBXIP1 PEBP4 PIK3R1 PIK51A PLCG2 PTK2 RASGRF2 TERF2IP | 31 |
| Formation of the beta-catenin:TCF transactivating complex              | BCL9 CPEB4 HIST2H2BE HOXD9 LYL1 MYC NIPAL4 POZG PYG02 RAB3A RBBP5 WWOX ZNF446 | 31 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | ANKRD46 DAA2M2 HIST2H2BE HOXD9 KMT2E LYL1 NIPAL4 POZG RAB3A RBBP5 ZNF446 | 31 |
| PD-1 signaling                                                         | ARHGEF4 ATXN7L2 HSBP1 MNS1 POZG VHL                                        | 31 |
| Phosphorylation of CD3 and TCR zeta chains | Translocation of ZAP-70 to Immunological synapse | ABCC12 ARHGEF4 ATXN7L2 HSBP1 POZG VHL | 31 |
| FCERI mediated Ca2+ mobilization | Role of phospholipids in phagocytosis | ABCC12 ETV7 IGSF9 MCMDC2 MEF2C MN1 PBXIP1 PEBP4 PIK3R1 PIK51A PLCG2 PTK2 RASGRF2 TERF2IP | 30 |
| SUMOylation of DNA damage response and repair proteins                 | ASNSD1 GUC2B HOXD9 LINCO1S87 NR3C2 NSMCE2 PHC3 SLC30A5 SSB TNNT2 TSPAN7 XRC4 | 30 |
| Ca2+ pathway                                                           | ETV7 GALE INTS8 MCMDC2 PEBP4 PIK51A PLCG2 PTK2 TERF2IP                    | 30 |
| DAG and IP3 signaling | PLC beta mediated events | VEGFR2 mediated cell proliferation | ETV7 MCMDC2 PEBP4 PIK51A PLCG2 PTK2 TERF2IP | 30 |
| Major pathway of rRNA processing in the nucleolus and cytosol          | AGO2 BCAN CDX1 CFHR4 DCDNC1 DUO1X1 FAM212B FCR1 K1 IDH1 KCNK4 KDEL1 KKL6 MYC NIP7 PDE6C PRKACA PROC RPIK3 RPI13A RPS23 RPS4X SEC24D SF3B4 STARD4 TLE2 ZCCH9 | 29 |
| Transcriptional regulation by small RNAs                               | AGO2 ASNSD1 BCAN GIMAP2 GUC2B HIST2H2BE HOXD9 LINCO1S87 LYL1 NIPAL4 NR3C2 RAB3A SLC30A5 SSB TNNT2 TSPAN7 ZNF446 | 29 |
| snRNP Assembly                                                         | ASNSD1 CFHR4 FGF GCG GEMIN7 GEMIN8 GUCA2B HOXD9 LINCO1S87 NR3C2 POZG SLC30A5 SSB TNNT2 TSPAN7 | 29 |
| GPV1-mediated activation cascade                                        | ABCC12 GALE IGSF9 INTS8 MEF2C MNS1 PBXIP1 PIK3R1 PIK51A PLCG2 PTK2 RASGRF2 TERF2IP | 29 |
| Estrogen-dependent gene expression                                     | AGO2 CHD1 HIST2H2BE IQGAP2 LYL1 MYC NIPAL4 PIEZO1 POZG RAB3A ZNF446        | 29 |
| FGF signaling pathway                                                  | ARHGEF4 COTL1 GAB2 PIK3R1 PLCG2 POZG PTK2 SELPLG TNFSF10                  | 29 |
| G alpha (q) signalling events                                          | INTS8 MN51 NPY4R PIK51A PLCG2 PTK2 TERF2IP                                | 29 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | DAA2M2 HIST2H2BE LYL1 NCOA6 NIPAL4 PARP10 PA56 PLCG2 POZG RAB3A RBBP5 VHL ZNF446 | 28 |
| PKMTs methylate histone lysines                                        | ASH1L DAA2M2 DQX1 KMT2E LYL1 MECOM PARP10 POZG RBBP5                     | 28 |
| G beta-gamma signalling through PLC beta                               | GALE INTS8 PIK51A PLCG2 PTK2 TERF2IP                                     | 28 |
| MHC class II antigen presentation                                      | DCTN4 GIMAP2 HSBP1 POZG RASGRF2 RILP                                     | 28 |

N = Total number of datasets in which pathway potentially disrupted

https://doi.org/10.1371/journal.pone.0213221.t003
unusually high number of significant targets for which it is predicted to be the best regulator; 33 in total (see Fig 4). It is not annotated with this pathway, and there is no path in Reactome from POGZ to known members of this pathway, so the pathway enrichment analysis is suggesting a novel involvement of POGZ in the pathway 'Formation of the beta-catenin:TCF transactivating complex', disruption of which is of relevance to tumor biology.

The pathway enrichment analysis of the predicted targets for POGZ infers a total of 17 enriched pathways (Table 4), fifteen of them in Reactome and two in Panther. The functional role of POGZ is, as yet, not well characterised in the literature and it is not annotated with these pathways, neither is there any path in Reactome or Panther from POGZ to known members of the pathways, so the enrichment analysis in conjunction with the meta-analysis is suggesting a novel involvement of POGZ in all of these pathways.

POGZ is known to encode a protein containing a zinc-finger cluster, an HP1-binding motif, a centromere protein-B-like DNA-binding (CENPB-DB) domain, and a transposase-derived DDE domain [62]. The HP1-binding domain of POGZ is required for mitotic progression and dissociation of HP1α from mitotic chromosome arms and for activation and dissociation of Aurora B kinase from chromosome arms at M phase [63]. POGZ has also been found to interact with glucocorticoid receptors, which regulate various metabolic, homeostatic and

### Table 4. Enriched pathways of POGZ with associated significant best targets.

| Pathway                                                                 | Targets                                                                 |
|------------------------------------------------------------------------|------------------------------------------------------------------------|
| TGF-beta signaling pathway                                             | ACVR2B EP400                                                           |
| EGF receptor signaling pathway;FGF signaling pathway                   | RASA1                                                                 |
| RNA polymerase II transcribes snRNA genes                              | SPS1 YY1 TRRAP EP400                                                   |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function;RUNX1 regulates transcription of genes involved in differentiation of HSCs | YY1 TRRAP KMT2A SMC4 EP400                                             |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis;Estrogen-dependent gene expression | YY1 TRRAP KMT2A SMC4 EP400                                             |
| Condensation of Prophase Chromosomes                                   | YY1 TRRAP KMT2A SMC4 EP400                                             |
| snRNP Assembly                                                         | GEMIN5                                                                |
| MHC class II antigen presentation                                       | SPS1 HLA-DPA1                                                         |
| Formation of the beta-catenin:TCF transactivating complex;Ub-specific processing proteases | YY1 TRRAP KMT2A SMC4 EP400                                             |
| PKMTs methylate histone lysines;RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function;RUNX1 regulates transcription of genes involved in differentiation of HSCs | YY1 TRRAP KMT2A SMC4 EP400                                             |
| Formation of the beta-catenin:TCF transactivating complex;HATs acetylate histones | YY1 TRRAP KMT2A SMC4 EP400                                             |
| HATs acetylate histones                                                | SPS1 YY1 TRRAP KMT2A SMC4 EP400                                       |
| DNA Damage Recognition in GG-NER                                        | YY1                                                                    |
| HATs acetylate histones;Ub-specific processing proteases               | TRRAP EP400                                                           |
| Formation of the beta-catenin:TCF transactivating complex;HATs acetylate histones;Ub-specific processing proteases | YY1 TRRAP KMT2A SMC4 EP400                                             |
| Downstream TCR signaling;Generation of second messenger molecules;Interferon gamma signaling;MHC class II antigen presentation;PD-1 signaling;Phosphorylation of CD3 and TCR zeta chains;Translocation of ZAP-70 to Immunological synapse | HLA-DPA1                                                             |
| Downstream TCR signaling;Generation of second messenger molecules;PD-1 signaling;Phosphorylation of CD3 and TCR zeta chains;Translocation of ZAP-70 to Immunological synapse | HLA-DPA1                                                             |

[https://doi.org/10.1371/journal.pone.0213221.t004](https://doi.org/10.1371/journal.pone.0213221.t004)
differentiation processes [64], and with the C terminus of LEDGF/p75 via its DDE domain [65, 66], and with trimethyl-lysine modifications on histones that control chromatin-mediated regulation of gene expression, and with the mitotic spindle checkpoint protein MAD2L2 [67].

POGZ has six significant best targets associated with the pathway 'Formation of the beta-catenin:TCF transactivating complex' in the enrichment analysis. TTRAP is annotated with this pathway in Reactome, EP400 and YY1 are centres of enriched local subnetworks, and SMC4, KMT2A and NAT8L are part of enriched local subnetworks.

If the stringency of the best regulator condition is relaxed (see Methods section for details), then more significant targets of POGZ appear in the pathway. Fig 5 plots the enriched network when the less stringent condition is applied. The enrichment analysis now associates sixteen significant targets for which POGZ is the best predicted regulator with the pathway.

Loss of function mutations in POGZ are known to be associated with severe neurodevelopmental delay, resulting in a majority of cells being unable to form metaphase plates, exiting mitosis prematurely and causing the formation of polyploidy cells, which can lead to cell death or genome instability in subsequent division cycles [68]. POGZ mutations that disrupt the DNA-binding activity of POGZ are also associated with Autism spectrum disorder (ASD) [62, 69, 70]. Loss of POGZ has also been found to affect the proliferation of mouse neural progenitor cells [71].

Another better characterised gene associated with ASD, CHD8, interacts with POGZ [72] and is known to be involved with beta-catenin pathways [73], and mutations in pathways regulating beta-catenin have been shown to occur in ASD [74]. POGZ expression is also correlated with CTNNND2 (Catenin Delta 2) [75], providing circumstantial support for POGZ’s involvement in the beta-catenin pathways predicted here by the pathway enrichment analysis of the regulatory relationships inferred from the meta-analysis of matched datasets.

Disruption of CHD8 is also implicated in cancer [76], as is the disruption of the destruction complex of beta-catenin [77]. Thus the genomic disruption of POGZ in many of the cancer datasets used in our study and the concomitant changes in its expression, and the significant correlation of the expression changes of an unusually high number of targets, may indicate that POGZ has a functional role in cancer biology. The datasets in which POGZ showed significant aCGH/expression correlation corresponded to the following tissues and cancer pathologies: Breast (ER+, ERBB2 amplified, Inflammatory), Head and Neck Squamous Cell, Lung Adenocarcinoma, Lymphoma, Multiple Myeloma, Osteosarcoma, Ovarian, Pancreatic, Prostate and Urothelial.

RBBP5 (RB Binding Protein 5) has significant self-correlation in 16 datasets. It is known to be involved in signaling by Wnt, and in Reactome it is annotated with the pathway ‘Formation of the beta-catenin:TCF transactivating complex’, as is one of its two significant best targets, SETDB2. Its other significant best target is SLTM. If the less stringent condition for RBBP5 to be the best regulator is applied then five further significant best targets are included in the pathway.

WWOX (WW Domain Containing Oxidoreductase) has significant self-correlation in 16 datasets. ‘Formation of the beta-catenin:TCF transactivating complex’, is an enriched pathway for WWOX due to its predicted significant best target LEFI. This prediction agrees with prior knowledge of WWOX in that it has a known regulatory relationship with LEFI involving the beta-catenin pathway. That is, WWOX interacts with DVL2, inhibiting the function of DVL2 in controlling the transcriptional activity of LEFI, and also by interacting with a cofactor of the Wnt/beta-catenin pathway, BCL9-2, to enhance the activity of the beta-catenin:TCF/LEF transcription factor complexes [78, 79]. WWOX is also known to act as a tumor suppressor [80].

If the less stringent condition for WWOX to be the best regulator is applied then five further significant best targets are included in the pathway, in addition to LEFI, namely SUV39H1,
TLE1, SIN3A, KDM4B and RCL1. None are annotated with this pathway but they are associated with the pathway by the enrichment analysis as either enriched centres or connected to enriched centres. Overexpression of SUV39H1 is known to be associated with cell proliferation in cancer [81]. SIN3A is downregulated in a variety of cancers and is thought to influence a specific step of tumorigenesis in part via the beta-catenin pathway [82]. KDM4B overexpression
contributes to the genesis of colorectal tumors via its role in beta-catenin mediated gene transcription [83].

CPEB4 (Cytoplasmic Polyadenylation Element Binding Protein 4) has significant self-correlation in 9 of the datasets and has 'Formation of the beta-catenin:TCF transactivating complex' as an enriched pathway through its significant best target TCF7L2. In Reactome CPEB4 is not connected to members of the pathway. Besides TCF7L2 it has four other significant best targets, namely NQO2, CES4A, TET1 and ZNF26. CES4A has no path to the pathway in Reactome, indicating that it may be a novel member of this pathway. If the less stringent condition is applied then the gene CROT is also a significant target of CPEB4 in this pathway.

CPEB4 has been shown to have a role in oncogenesis through translational activation of mRNAs that are normally silenced [84]. Silencing of CPEB4 prevents cell invasion and migration in non-small cell lung cancer [85]. High CPEB4 expression can serve as a prognostic factor in invasive ductal breast carcinoma [86]. The related gene CPEB1 regulates beta-catenin mRNA translation [87].

MYC (MYC Proto-Oncogene) has significant self-correlation in 8 of the datasets and is known to be part of the pathway 'Formation of the beta-catenin:TCF transactivating complex'. Similarly PYGO2 (Pygopus Family PHD Finger 2), with significant self-correlation in 7 datasets, is also annotated with this pathway in Reactome.

Pathway example 2: RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function. RUNX1 is a transcription factor, known to be essential for the maturation of megakaryocytes [88]. It is known as a tumor suppressor in leukemia but has recently been implicated to have a role in other cancer types [89, 90]. A total of eleven regulators have their target lists enriched with this pathway in Metamatched, namely POGZ (20), ANKRD46 (17), RBBP5 (16), KMT2E (9), DAAM2 (4), LYL1 (3), ZNF446 (3), HOXD9 (2), NIPAL4 (2), HIST2H2BE (2) and RAB3A (2).

POGZ (Pogo Transposable Element Derived With ZNF Domain): There is no path in Reactome from POGZ to members of the pathway 'RUNX1 regulates genes involved in megakaryocyte differentiation' however it has been shown that POGZ is highly expressed in mouse megakaryocyte erythroid progenitors [71].

Five of the thirty three significant best targets of POGZ are associated with the pathway in the enrichment analysis. Of the five, KMT2A is annotated with this pathway in Reactome, EP400 and YY1 are at the centres of enriched local subnetworks, and SMAC and TRRAP are part of enriched local subnetworks. Of the remaining 28, 11 do not currently appear in Reactome, one occurs but has no path to any members of the pathway, and 14 do have paths to members of this pathway. If the less stringent condition for a regulator to be the best regulator is applied then a further four significant best targets are associated with the pathway, namely MORF4L1, MORF4L2, MTA1 and YEATS2.

ANKRD46 (Ankyrin Repeat Domain 46) is also not known to be part of this pathway, but is associated in this analysis by gene KAT2B being a significant best target. Whereas, RBBP5 (RB Binding Protein 5, Histone Lysine Methyltransferase Complex Subunit) and KMT2E (Lysine Methyltransferase 2E) are both annotated with this pathway in Reactome.

Pathway example 3: HDMs demethylate histones. By removing methyl groups from histone proteins Histone demethylases (HDMs) contribute to epigenetic regulation by reversing histone methylation [91] and given their epigenetic role they are of interest as therapeutic targets in cancer [92].

In Metamatched three regulators have this pathway enriched in their target lists: DERL1 (21), MAN2A1 (13) and POLD3 (11). Fig 6 shows a simplified pathway diagram derived by amalgamating the results of the enrichment analysis for these three regulators.
DERL1 (Derlin1) is a component of the endoplasmic reticulum-associated mechanism for the degradation of misfolded proteins. It demonstrates significant self-correlation in 21 of the datasets and has 3 significant best targets, JMJD6, ZKSCAN7 and CCPG1. Its main pathway from the enrichment analysis is 'HDMs demethylate histones'. DERL1 is not known to be part of this pathway, but in Reactome it has a path to members of the pathway by way of forming a complex with RAD23B, which in turn is connected to SUMO1. Significant best target JMJD6 is associated with the pathway. Of the two other significant best targets CCPG1 does not currently appear in Reactome whilst ZKSCAN7 does have a path to members of this pathway. If
the stringency of the condition for a regulator to be a target’s best regulator is relaxed then
*POLD3* is also included as a significant best target. *POLD3* (see below) is itself a potential regu-
lator in the Metamatched analysis and interestingly its own target list is also enriched with the
pathway ‘HDMs demethylate histones’.

*POLD3* (DNA Polymerase Delta 3, Accessory Subunit) plays an important role in DNA repli-
cation and repair. Depletion of *POLD3* results in an increase in genome instability, by way of
breaks, S-phase progression impairment and chromosome abnormalities [93]. It has self corre-
lation in 11 datasets and has 7 significant best targets, one of which, *PHF2*, is associated with
this pathway. Four of the others have some path to the pathway and two do not appear in React-
tome. *POLD3* has a path to *PHF2* via *POLR2A*. If the less stringent condition is applied then
five further significant best targets are associated with the pathway, *DOT1L, RARG, SUPT5H, TAF1L*
and *PDCD7*.

*MAN2A1* (Mannosidase Alpha Class 2A Member 1) has self correlation in 13 datasets and
one significant best target, *KDM4A*. *MAN2A1* is not annotated with this pathway, but can be
connected to members of the pathway in Reactome.

**Discussion**

Previously we have used matched aCGH/expression datasets to predict statistically significant
gene regulatory relationships [3], validated the method experimentally [1] and computa-
tionally [2]. In this context regulatory relationship refers to more than just direct casual relation-
ships of transcription factors on targets, encompassing indirect casual relationships as well,
through pathways containing intermediate regulatory steps.

The data used in the analysis consists of more than three thousand cancer samples so in this
paper we explore whether the results can provide insights into tumor biology. To this end we
have carried out an exhaustive network-based pathway enrichment analysis. We concentrate
on those genes that are unusual in manifesting copy number heterogeneity, and a concomit-
ant change in expression, in many of the 45 datasets and a very wide variety of different cancer
types.

This consistent heterogeneity could indicate genes located in genomic regions which are
prone to disruption in cancer cells, but this disruption occurs only sporadically amongst sam-
pies, suggesting little relevance to the actual cancer pathology. However it is known that genes
are rarely altered in more than 10% of tumors for any type of cancer [11] and there is a com-
plex interplay of alterations within pathways in cancer [12]. So disruption of more than one
member of a pathway in an inconsistent manner across samples could result in that pathway
being consistently disrupted in all of the samples. We plan to explore this aspect of the data
further in future work since it has been recognised that phenotypic heterogeneity between
tumors, in terms of the pathways disrupted, is much less than the observed genetic heterogene-
ity [94].

An alternative possibility is that these genes occur in genomic regions which are disrupted
consistently in the later stages of tumor development. In general the samples within an exper-
iment will come from tumors at different stages of the disease, so the disruption to these partic-
ular genes may reflect changes that take place during the course of tumor development. In this
case the disruption to regulators and their pathways might have a role in later phases of the dis-
ease, for example in the development of metastases. Along with tumor heterogeneity, meta-
stases are a major challenge facing cancer therapy [95].

In some cases the pathway enrichment analysis predicts known down-stream target genes
of a regulator, and some examples of this feature in the Results section. In other cases however
known down-stream targets are not predicted. Such missing predictions may be due to lack of
predictive power of the analysis. Alternatively they may result from cellular mechanisms able to compensate for a regulator’s copy number disruption and concomitant change in expression. For example, they may represent regulator-target relationships that are highly non-linear so that large changes in a regulator’s expression has little effect on down-stream components of the pathway. Activation of an alternative pathway, or pathways, that can compensate for the disruption to a pathway is another possible method for nullifying the effects of changes in a regulator’s expression.

If cellular mechanisms are responsible, then the analysis presented here may be highlighting those regulator-target relationships that lack redundancy or any buffering process in the cell. They are relationships where disruption to the regulator’s expression, due to changes in its copy number, cannot be compensated for by the cell and so may have a real functional effect. The genetic diversity of tumors is a major problem in cancer therapy and the aim of personalized cancer therapy is to identify mutations that are clinically relevant. This involves distinguishing ‘driver’ mutations from neutral ‘passenger’ mutations that tend to accumulate during tumorgenesis [11, 96]. If this study is highlighting functionally important regulators, then some of these may be ‘driver’ genes whose disruption is relevant to tumor biology.

So despite the inconsistent disruption of the copy number across samples of the genes in this study, it is possible to hypothesize that these genes could be regulators that have a role in tumor biology. The pathway memberships predicted by the network analysis of the meta-analysis results do suggest a close involvement of some of these genes in known cancer pathways. This includes genes for which there is currently little or no information on their relevance to cancer, especially multiple types of cancer, but which have cancer related pathways enriched in the target lists predicted for them by the meta-analysis of matched experiments.

The pathway enrichment analysis shows some interesting examples of direct validation, for example the relationship between WWOX and LEF1 in the beta-catenin pathway, and circumstantial validation, for example the enrichment of the target list of POGZ with the megakaryocytes and beta-catenin pathways.

In order to reduce false positives we use high confidence levels and a stringent condition as to whether a regulator is the best regulator for a target in our analysis. Inevitably the stringency may remove some true positives. An example can be seen in the results for the regulator WWOX where applying the less stringent condition reveals further significant best targets known to be involved with beta-catenin pathways. Consequently the Metamatched database also provides the significant targets of a regulator found using the less stringent condition for a regulator to be the best regulator of a target.

The work highlights those genes disrupted in many of the datasets. One of the most interesting of these regulators is POGZ. It stands out in having self aCGH/expression correlation in a large number of datasets and cancer types, and also an unusually high number of predicted significant targets (Fig 3) and some novel enriched pathways. Whilst not connected in Reactome to these pathways, and not yet well characterised in the literature, prior knowledge of the role of the gene POGZ does provide some support for the enriched pathways predicted by the network analysis presented here.

A major advantage of the analytical approach used, that is correlation of aCGH with expression, is that it avoids the risk of confounding that can occur when using the correlation of expression profiles alone. One problem of the analysis is the potential difficulty of distinguishing the targets of two regulators which are neighbours in the genome and are often co-disrupted. The more datasets in which a regulator demonstrates copy number disruption, the less likely this will occur. The relationships that can be investigated are also necessarily constrained by the probes that are available on the arrays used in the experiments.
The aim of the predictions in the Metamatched database is to inform experiments and provide information for generating gene regulatory networks. Since our analysis builds on the causal influence of the regulator gene on its target, the predictions of pathway membership may help to infer the downstream effects of drugs on their targets.

As discussed in more detail in our previous publication [3] it is possible that some of the predicted relationships in this study have arisen through a confounding factor as part of some as yet poorly understood or unknown genetic mechanisms. For example histone modification regulated by microRNAs promoting copy number variation [97, 98] or hypoxia-dependent copy gain [99] are possible mechanisms by which confounding could occur. This means that as well as detecting direct interactions, and indirect ones through pathways, the analysis may be detecting subtler genomic effects, which cannot be isolated with current knowledge.

In future work we plan to explore whether the inconsistent genomic disruption of multiple genes within a dataset leads to a more consistent phenotypic disruption of the samples in terms of pathways altered. It would be interesting to identify which subsets of regulators are required to be altered to consistently perturb a particular pathway within a dataset, where these genes are positioned in the pathway and what role they perform there. We also plan to update the METAMATCHED database in line with updates to PathwayCommons, GO and cocitation information, and to integrate the results with other oncogenomics databases. In addition there are alternative analysis methods which could be employed, for example, Pearson correlation, or maximal information-based nonparametric exploration statistics [100], a technique designed to cope with non-linearities in the data being analysed.

Conclusion

We have added information from an exhaustive network-based pathway enrichment analysis to METAMATCHED, a database of statistically significant regulator-target predictions. In this paper we explore the relevance of these results to tumor biology. We have concentrated on genes exhibiting consistent heterogeneous copy number disruption and presented arguments why these genes could be of relevance to cancer pathways, which appear to be supported by the pathway enrichment results. The wealth of predicted regulatory relationships and pathway memberships contained in the Metamatched database provide pointers as to possible experiments that could clarify their role in cancer. We demonstrate how the predictions contained in the database can be useful in informing experiments and extending networks of regulatory relationships. We provide some interesting examples of this process, in particular for the gene POGZ.

Supporting information

S1 File. Supplementary information for methods and results sections.
(PDF)

S2 File. Summary results for 2172 regulators. A spreadsheet that summarises the Meta-matched results for 2172 regulators that have at least one significant predicted target (adjusted p-value < 0.1).
(CSV)

S3 File. Complete results for 2172 regulators. Results for 2172 genes, in R archive format. Unpacks as an R list object named ‘regulators.details’ with a format described in S1 File.
(RDATA)

S4 File. Supplementary tables.
(PDF)
S5 File. Supplementary results—Network analysis.
(PDF)

Author Contributions

**Conceptualization:** Richard Newton, Lorenz Wernisch.

**Data curation:** Richard Newton.

**Formal analysis:** Richard Newton.

**Funding acquisition:** Lorenz Wernisch.

**Investigation:** Richard Newton, Lorenz Wernisch.

**Methodology:** Richard Newton, Lorenz Wernisch.

**Project administration:** Lorenz Wernisch.

**Software:** Richard Newton.

**Supervision:** Lorenz Wernisch.

**Writing – original draft:** Richard Newton.

**Writing – review & editing:** Lorenz Wernisch.

References

1. Goh XY, Newton R, Wernisch L, Fitzgerald R. Testing the Utility of an Integrated Analysis of Copy Number and Transcriptomics Datasets for Inferring Gene Regulatory Relationships. PLoS ONE. 2013; 8:e63780. https://doi.org/10.1371/journal.pone.0063780

2. Newton R, Wernisch L. A Meta-Analysis of Multiple Matched Copy Number and Transcriptomics Data Sets for Inferring Gene Regulatory Relationships. PLoS ONE. 2014; 9(8):e105522. https://doi.org/10.1371/journal.pone.0105522 PMID: 25148247

3. Newton R, Wernisch L. Investigating inter-chromosomal regulatory relationships through a comprehensive meta-analysis of matched copy number and transcriptomics data sets. BMC Genomics. 2015; 16(1):967. https://doi.org/10.1186/s12864-015-2100-5 PMID: 26581858

4. Newton R, Wernisch L. METAMATCHED; 2018. Available from: http://sysbio.mrc-bsu.cam.ac.uk/METAMATCHED.

5. Huang N, Shah PK, Li C. Lessons from a decade of integrating cancer copy number alterations with gene expression profiles. Briefings in Bioinformatics. 2011; 13:305–316. https://doi.org/10.1093/bib/bbr056 PMID: 21949216

6. Lahti L, Schäfer M, Klein HU, Bicciato S, Dugas M. Cancer gene prioritization by integrative analysis of mRNA expression and DNA copy number data: a comparative review. Briefings in Bioinformatics. 2012. https://doi.org/10.1093/bib/bbs005 PMID: 22441573

7. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463:899–905. https://doi.org/10.1038/nature08822 PMID: 20164920

8. Cerami EG, Gross BE, Demir E, Redchenkov I, Babur O, Anwar N, et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Research. 2011; 39(suppl_1):D685–D690. https://doi.org/10.1093/nar/gkq1039 PMID: 21071392

9. Gwinner F, Boulday G, Vandledonck C, Arnould M, Cardoso C, Nikolayeva I, et al. Network-based analysis of omics data: the LEAN method. Bioinformatics. 2017; 33(5):701–709. https://doi.org/10.1093/bioinformatics/btw676 PMID: 27797778

10. R Core Team. R: A Language and Environment for Statistical Computing; 2018. Available from: http://www.R-project.org/.

11. Mroz EA, Rocco JW. The challenges of tumor genetic diversity. Cancer. 2017; 123(6):917–927. https://doi.org/10.1002/cncr.30430 PMID: 27861749
12. Sanchez-Vega F, Mina M, Arumenia J, Chatila W, Luna A, La K, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018; 173(2):321–337. https://doi.org/10.1016/j.cell.2018.03.035 PMID: 29625050

13. Parris TZ, Danielsson A, Nemes S, Kovács A, Delle U, Fallenius G, et al. Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma. Clinical Cancer Research. 2010; 16:3860–3874. https://doi.org/10.1158/1078-0432.CCR-10-0889 PMID: 20551037

14. Crowder RJ, Phommalay C, Tao Y, Hoog J, Luo J, Perou CM, et al. PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer. Cancer Research. 2009; 69:3955–3962. https://doi.org/10.1158/0008-5472.CAN-08-4450 PMID: 19367695

15. Sircolofb F, Békhouché I, Finetti P, Adélaïde J, Hamida AB, Bonansea J, et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer. 2010; 10:539. https://doi.org/10.1186/1471-2407-10-539 PMID: 20932292

16. Myllrykangas S, Junnila S, Kokkola A, Autio R, Scheinin I, Kiviluoto T, et al. Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int J Cancer. 2008; 123:817–825. https://doi.org/10.1002/ijc.23574 PMID: 18506690

17. Junnila S, Kokkola A, Karjalainen-Lindsberg ML, Puolakkainen P, Monni O. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer. 2010; 10.73. https://doi.org/10.1186/1471-2470-10-73 PMID: 20178983

18. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene. 2009; 6:2773–2783. https://doi.org/10.1038/onc.2009.135

19. Goh XY, Rees JR, Paterson AL, Chin SF, Marioni JC, Save V, et al. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut. 2011; 60:1317–1326. https://doi.org/10.1136/gut.2010.234179 PMID: 21478220

20. Zhou Y, Zhang Q, Stephens O, Heuck CJ, Tian E, Sawyer JR, et al. Prediction of cytogenetic abnormalities with gene expression profiles. Blood. 2012; 119:e148–e150. https://doi.org/10.1182/blood-2011-10-388702 PMID: 22496154

21. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodelers as a central tumor suppressive complex in pancreatic cancer. Proc Nat Acad Sci. 2012; 109:252–259. https://doi.org/10.1073/pnas.1114817109

22. Vainio P, Wolf M, Edgren H, He T, Kohonen P, Mpindi JP, et al. Integrative Genomic, Transcriptomic, and RNAi Analysis Indicates a Potential Oncogenic Role for FAM110B in Castration-Resistant Prostate Cancer. The Prostate. 2012; 72:789–802. https://doi.org/10.1002/pros.21487 PMID: 21919029

23. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nature Genetics. 2011; 43:668–674. https://doi.org/10.1038/ng.855 PMID: 21642991

24. Bekhouche I, Finetti P, Adélaïde J, Ferrari A, Tarpin C, Charafte-Jauffret E, et al. High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes. PlosOne. 2011; 6:e16950. https://doi.org/10.1371/journal.pone.0016950

25. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471:467–472. https://doi.org/10.1038/nature09837 PMID: 21430775

26. Ooi WF, Re A, Sidarovich V, Canella V, Arseni N, Adami V, et al. Segmental Chromosome Aberrations Converge on Oxenoverexpression of Mitotic Spindle Regulatory Genes in High-Risk Neuroblastoma. Genes, Chromosomes and Cancer. 2012; 51:545–556. https://doi.org/10.1002/gcc.21940 PMID: 22337647

27. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, et al. Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström’s Macroglobulinemia. Cancer Research. 2009; 69:3579–3588. https://doi.org/10.1158/0008-5472.CAN-08-3701 PMID: 19351844

28. Jönsson G, Staal J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Research. 2010; 12:R42. https://doi.org/10.1186/bcr2596 PMID: 20576095

29. Muranen TA, Greco D, Fagerholm R, Klipivaa O, Kämpärvi K, Alttomäki K, et al. Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications. Breast Cancer Research. 2011; 13:R90. https://doi.org/10.1186/bcr3015 PMID: 21542898
30. Lindgren D, Frigyesi A, Gudjonsson S, Sjödahl G, Hallen C, Chebil G, et al. Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome. Cancer Research. 2010; 70:3463–3472. https://doi.org/10.1158/0008-5472.CAN-09-4213 PMID: 20406976

31. Beck AH, Lee CH, Witten DM, Gleason BC, Edris B, Espinosa I, et al. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene. 2010; 29:845–862. https://doi.org/10.1038/onc.2009.381 PMID: 20473936

32. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. International Journal of Cancer. 2011; 128:1095–1103. https://doi.org/10.1002/ijc.25448 PMID: 20473936

33. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012; 486:353–360. https://doi.org/10.1038/nature11143 PMID: 22722193

34. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487:239–243. https://doi.org/10.1038/nature1125 PMID: 22722302

35. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008; 105:13520–13525. https://doi.org/10.1073/pnas.0804251105 PMID: 18765795

36. Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, Lövgren K, et al. Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma. PlosOne. 2012; 7:e38863. https://doi.org/10.1371/journal.pone.0038863

37. Micci F, Panagopoulos I, Haugum L, Dahlback HS, Pretorius ME, Davidson B, et al. Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva. Genes Chromosomes Cancer. 2013; 52:551–563. https://doi.org/10.1002/gcc.22053 PMID: 23404381

38. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative Genomic Profiling of Human Prostate Cancer. Cancer Cell. 2010; 18:11–22. https://doi.org/10.1016/j.ccr.2010.05.026 PMID: 20579941

39. Coco S, Theissen J, Scaruffi P, Stigliani S, Moretti S, Oberthuer A, et al. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma. International Journal of Cancer. 2012; 131:1591–1600. https://doi.org/10.1002/ijc.27432 PMID: 22234802

40. Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S, et al. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Human Molecular Genetics. 2009; 18:1349–1352. https://doi.org/10.1093/hmg/ddp034 PMID: 19153074

41. Przybyl J, Sciot R, Wozniak A, Schoöfski P, Vanspa uwen V, Samson I, et al. Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. The International Journal of Biochemistry & Cell Biology. 2014; 53(0):505–513. https://doi.org/10.1016/j.biocel.2014.05.006

42. Huang RY, Chen GB, Matsumura N, Lai HC, Mori S, Li J, et al. Histotype-specific copy-number alterations in ovarian cancer. BMC Medical Genomics. 2012; 5(1):47. https://doi.org/10.1186/1755-8794-5-47 PMID: 23078675

43. Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, et al. An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735. Molecular Cancer Therapeutics. 2012; 11(3):710–719. https://doi.org/10.1158/1535-7163.MCT-11-014 PMID: 22226311

44. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, et al. Integrative Analysis Reveals an Outcome-associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B-cell Lymphoma. Cancer cell. 2012; 22:359–372. https://doi.org/10.1016/j.ccr.2012.07.014 PMID: 22975378

45. Ross-Adams H, Lamb A, Dunning M, Halim S, Lindberg J, Massie CM, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine. 2015; 2:1133–1144. https://doi.org/10.1016/j.ebiom.2015.07.017 PMID: 26501111

46. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, Speed TP, et al. Identification of Candidate Growth Promoting Genes in Ovarian Cancer through Integrated Copy Number and Expression Analysis. PLOS ONE. 2010; 5(4):1–12. https://doi.org/10.1371/journal.pone.0009983

47. Guarnieri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, et al. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
48. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, et al. Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation. PLOS ONE. 2012; 7(5):1–13. https://doi.org/10.1371/journal.pone.0036530

49. Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, et al. Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer. Clinical Cancer Research. 2012; 18(5):1352–1363. https://doi.org/10.1158/1078-0432.CCR-11-1539 PMID: 22621810

50. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, et al. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes, Chromosomes and Cancer. 2012; 51(7):696–706. https://doi.org/10.1002/gcc.21956 PMID: 22454324

51. Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevosian RG, et al. Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma. Journal of Clinical Oncology. 2011; 29(30):3999–4006. https://doi.org/10.1200/JCO.2011.35.5677 PMID: 21931021

52. Weigelt B, Ng C, Shen R, Popova T, Schizas M, Natrajan R, et al. Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Modern pathology. 2015; 28(3):340–351. https://doi.org/10.1038/modpathol.2014.142 PMID: 25412848

53. Romero P, Wagg J, Green M, Kaiser D, Krummenacker M, Karp P. Computational prediction of human metabolic pathways from the complete human genome. Genome Biology. 2004. https://doi.org/10.1186/gb-2004-6-1-r2 PMID: 15642094

54. Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, et al. PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Research. 2017; 45(D1):D183–D189. https://doi.org/10.1093/nar/gkw1138 PMID: 27899595

55. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID: the Pathway Interaction Database. Nucleic Acids Research. 2009; 37(suppl_1):D674–D679. https://doi.org/10.1093/nar/gkn653 PMID: 18832364

56. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The Reactome Pathway Knowledgebase. Nucleic Acids Research. 2018; 46(D1):D649–D655. https://doi.org/10.1093/nar/gkx1132 PMID: 29145629

57. NIH. Pubmed, US National Library of Medicine, National Institutes of Health; 2018. Available from: http://www.ncbi.nlm.nih.gov/pubmed/

58. Csardi G, Nepusz T. The igraph software package for complex network research. InterJournal. 2006; Complex Systems: 1695.

59. Li DM, Sun H. TEP1, Encoded by a Candidate Tumor Suppressor Locus, Is a Novel Protein Tyrosine Phosphatase Regulated by Transforming Growth Factor β. Cancer Research. 1997; 57(11):2124–2129. PMID: 9187108

60. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proceedings of the National Academy of Sciences. 1997; 94(17):9052–9057. https://doi.org/10.1073/pnas.94.17.9052

61. Clevers H. Wnt/β-Catenin Signaling in Development and Disease. Cell. 2006; 127(3):469–480. https://doi.org/10.1016/j.cell.2006.10.018. PMID: 17081971

62. Matsumura K, Nakazawa T, Nagayasu K, Gotoda-Nishimura N, Kasai A, Hayata-Takano A, et al. De novo POGZ mutations in sporadic autism disrupt the DNA-binding activity of POGZ. Journal of Molecular Psychiatry. 2016; 4(1):1. https://doi.org/10.1186/s40303-016-0016-x PMID: 27103995

63. Nozawa RS, Nagao K, Masuda HT, Iwasaki O, Hirota T, Nozaki N, et al. Human POGZ modulates dissociation of HP1α from mitotic chromosome arms through Aurora B activation. Nature Cell Biology. 2010; 12:719. https://doi.org/10.1038/ncb2075 PMID: 20562864

64. Lempila¨inen J, Niskanen E, Vuoti KM, Lampinen ER, Góöös H, Varjosalo M, et al. Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping. Molecular & Cellular Proteomics. 2017; 16:mcp.M117.067488.

65. Bartholomeeusen K, Christ F, Hendrix J, Rain JC, Emiliani S, Benarous R, et al. Lens Epithelium-derived Growth Factor/p75 Interacts with the Transposase-derived DDE Domain of PogZ. Journal of Biological Chemistry. 2009; 284(17):11467–11477. https://doi.org/10.1074/jbc.M807781200 PMID: 19244240

66. Tesina P, Čermáková K, Hořejší M, Procházková K, Fábyr M, Sharma S, et al. Multiple cellular proteins interact with LEDGF/p75 through a conserved unstructured consensus motif. Nature Communications. 2015; 6:7968. https://doi.org/10.1038/ncomms8968 PMID: 26245978
67. Vermeulen M, Eberli HC, Matarese F, Marks H, Denissen S, Butter F, et al. Quantitative Interaction Proteomics and Genome-wide Profiling of Epigenetic Histone Marks and Their Readers. Cell. 2010; 142(6):967–980. https://doi.org/10.1016/j.cell.2010.08.020 PMID: 20850016

68. Ye Y, Cho MT, Retterer K, Alexander N, Ben-Omran T, Al-Mureikhi M, et al. De novo POGZ mutations are associated with neurodevelopmental disorders and microcephaly. Cold Spring Harbor Molecular Case Studies. 2015; 1(1):a000455. https://doi.org/10.1101/mcs.a000455 PMID: 27148570

69. Stessman HF, Willemsen M, Fencvoka M, Penn O, Hoischen A, Xiong B, et al. Disruption of POGZ Is Associated with Intellectual Disability and Autism Spectrum Disorders. The American Journal of Human Genetics. 2016; 9(3):541–552. https://doi.org/10.1016/j.ajhg.2016.02.004

70. White J, Beck CR, Harel T, Posey JE, Jhangiani SN, Tang S, et al. POGZ truncating alleles cause syndromic intellectual disability. Genome Medicine. 2016; 8(1):3. https://doi.org/10.1186/s13073-015-0253-0 PMID: 26739615

71. Gudmundsdottir B, Gudmundsson KO, Klarmann KD, Singh SK, Sun L, Singh S, et al. POGZ Is Required for Silencing Mouse Embryonic Beta-like Hemoglobin and Human Fetal Hemoglobin Expression. Cell Reports. 2018; 23(11):3236–3248. https://doi.org/10.1016/j.celrep.2018.05.043 PMID: 29898395

72. Cotney J, Muhle RA, Sanders SJ, Liu L, Willsey AJ, Niu W, et al. The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment. Nature Communications. 2015; 6(6404). https://doi.org/10.1038/ncomms7404 PMID: 25752243

73. Thompson BA, Tremblay V, Lin G, Bochar DA. CHD8 Is an ATP-Dependent Chromatin Remodeling Factor That Regulates β-Catenin Target Genes. Molecular and Cellular Biology. 2008; 28(12):3894–3904. https://doi.org/10.1128/MCB.00322-08 PMID: 18378692

74. O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012; 485(7397):246–250. https://doi.org/10.1038/nature10989 PMID: 22495309

75. Turner TN, Sharma K, Oh EC, Liu YP, Collins RL, Sosa MX, et al. Loss of delta catenin function in severe autism. Nature. 2015; 520(7545):51–56. https://doi.org/10.1038/nature14186 PMID: 25807484

76. Bernier R, Golzo C, Xiong B, Stessman H, Coe B, Penn O, et al. Disruptive CHD8 Mutations Define a Subtype of Autism Early in Development. Cell. 2014; 158(2):263–276. https://doi.org/10.1016/j.cell.2014.06.017 PMID: 24998929

77. Bourroul GM, Fragoso HJ, Gomes JWF, Bourroul VSO, Oshima CTF, Gomes TS, et al. The destruction complex of beta-catenin in colorectal carcinoma and colonic adenoma. Einstein. 2016; 14(2):135–215. https://doi.org/10.1590/S1679-45082016AC03678 PMID: 27462886

78. Bouteille N, Driouch K, Hage PE, Sin S, Formstecher E, Camonis J, et al. Inhibition of the Wnt/β-Catenin Coactivator BCL9-2 in Breast Cancer Cells. Molecular Cancer Research. 2015; 13(5):902–912. https://doi.org/10.1158/1535-7597.MCR-14-0180 PMID: 25678599

79. El-Hage P, Petitlatot A, Monsoro-Burq AH, Maczkowiz F, Driouch K, Formstecher E, et al. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells. Molecular Cancer Research. 2015; 13(5):902–912. https://doi.org/10.1158/1555-7186.MCR-14-0180 PMID: 25678599

80. Lo JY, Chou YT, Lai FJ, Hsu LJ. Regulation of cell signaling and apoptosis by tumor suppressor WWOX. Experimental Biology and Medicine. 2015; 240(3):383–391. https://doi.org/10.1175/153537021466747 PMID: 25959191

81. Spyropoulou A, Gargallianos A, Dalagiorgou G, Adamopoulos C, Papavassiliou KA, Lea RW, et al. Role of Histone Lysine Methyletransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation. NeuroMolecular Medicine. 2014; 16(1):70–82. https://doi.org/10.1007/s12017-013-8254-x PMID: 23943221

82. Das T, Sangodkar J, Negre N, Narla G, Cagan R. Sln3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene. 2013; 32(26):3184–3197. https://doi.org/10.1038/onc.2012.326 PMID: 22890320

83. Berry W, Kim T, Janknecht R. Stimulation of β-catenin and colon cancer cell growth by the KDM4B histone demethylase. International Journal of Oncology. 2014; 44:1341–1348. https://doi.org/10.3892/ijo.2014.2279 PMID: 24481461

84. Ortiz-Zapater E, Pineda D, Martinez-Bosch N, Fernández-Miranda G, Iglesias M, Alameda F, et al. Key contribution of CPEB4-mediated translational control to cancer progression. Nature Medicine. 2011; 18:83. https://doi.org/10.1038/nm.2540 PMID: 22138752

85. Jing H, LiBin Z, Qiang C, Jie L, ShaoBo W, Ri L, et al. Knockdown of CPEB4 expression suppresses cell migration and invasion via Akt pathway in non-small cell lung cancer. Cell Biology International. 2018; 42(11):1484–1491. https://doi.org/10.1002/cbin.10930
86. Sun H, Wen X, Han T, Liu Z, Li S, Wang J, et al. Expression of CPEB4 in invasive ductal breast carcinoma and its prognostic significance. Oncotargets and Therapy. 2015; 8:3499–3506. https://doi.org/10.2147/OTT.S87587 PMID: 26648741
87. Jones KJ, Korb E, Kandel MA, Kochanek AR, Kabraji S, McEvoy M, et al. CPEB1 Regulates β-Catenin mRNA Translation and Cell Migration in Astrocytes. Glia. 2008; 56(13):1401–1413. https://doi.org/10.1002/glia.20707 PMID: 18618654
88. Pencovich N, Jaschek R, Dicken J, Amit A, Lotem J, Tanay A, et al. Cell-Autonomous Function of Runx1 Transcriptionally Regulates Mouse Megakaryocytic Maturation. PLOS ONE. 2013; 8(5):1–11. https://doi.org/10.1371/journal.pone.0064248
89. Mercado-Matos J, Matthew-Onabanjo A, Shaw L, RUNX1 and breast cancer. Oncotarget. 2017; 8(23):36934–36935. https://doi.org/10.18632/oncotarget.17249 PMID: 28455962
90. Riggo AI, Blyth K. The enigmatic role of RUNX1 in female-related cancers—current knowledge & future perspectives. The FEBS Journal. 2017; 284(15):2345–2362. https://doi.org/10.1111/febs.14059 PMID: 28304148
91. Shi YG, Tsukada Y. The Discovery of Histone Demethylases. Cold Spring Harb Perspect Biol. 2013; 5(9):a017947. https://doi.org/10.1101/cshperspect.a017947 PMID: 24003214
92. D’Oto A, Tian Q, Davidoff A, Yang J. Histone demethylases and their roles in cancer epigenetics. J Med Oncol Ther. 2016; 1(2):34–40. PMID: 28149961
93. Tumini E, Barroso S, Calero CP, AguilerA. Roles of human POLD1 and POLD3 in genome stability. Scientific Reports. 2016; 6:38873. https://doi.org/10.1038/srep38873 PMID: 27974823
94. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501:338. https://doi.org/10.1038/nature12625 PMID: 24048066
95. Fidler UJ, Kripke ML. The challenge of targeting metastasis. Cancer and Metastasis Reviews. 2015; 34(4):635–641. https://doi.org/10.1007/s10555-015-9586-9 PMID: 26328524
96. Chowell D, Napier J, Gupta R, Anderson KS, Maley CC, Sayres MAW. Modeling the Subclonal Evolution of Cancer Cell Populations. Cancer Research. 2018; 78(3):830–839. https://doi.org/10.1158/0008-5472.CAN-17-1229 PMID: 29187407
97. Black JC, Manning AL, Van Rechem C, Kim J, Ladd B, Cho J, et al. KDM4A Lysine Demethylase Induces Site-Specific Copy Gain and Rereplication of Regions Amplified in Tumors. Cell. 2013; 154(3):541–555. http://dx.doi.org/10.1016/j.cell.2013.06.051. PMID: 23871696
98. Black JC, Zhang H, Kim J, Getz G, Whetstine JR. Regulation of Transient Site-specific Copy Gain by MicroRNA. Journal of Biological Chemistry. 2016; 291(10):4862–4871. https://doi.org/10.1074/jbc.M115.711648 PMID: 26755726
99. Black JC, Aatabakhsh E, Kim J, Biette KM, Van Rechem C, Ladd B, et al. Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. Genes & Development. 2015; 29(10):1018–1031. https://doi.org/10.1101/gad.259796.115
100. Filosi M, Visintainer R, Albanese D. minerva: Maximal Information-Based Nonparametric Exploration R package for Variable Analysis; 2014. Available from: http://CRAN.R-project.org/package=minerva.